British Biotech hurt by results of drug trials
Article Abstract:
British Biotech PLC announced that its Marimastat cancer drug experienced another clinical trial. The pancreatic cancer drug's failure led to an approximately 40% decline in the company's value.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Alliance's pretax profit falls 9.5%, hurt by competition
Article Abstract:
Alliance and Leicester PLC posted a decline of 9.5% in pretax profits for the 2000 year. The company posted 446.7 million pounds (708.4 million euros) in pretax profits.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Pharmacia cancer drug is approved by U.S
Article Abstract:
Pharmacia & Upjohn Inc. has been given approval for its breast-cancer drug in the US. The epirubicin drug has already been in use in other countries for several years now. The drug will be marketed under the Ellence name. It had sales of $177 million (170 million euros) in sales in 80 countries in 1998. The drug was approved by the US Food and Drug Administration.
Comment:
Given approval for epirubicin breast-cancer drug in the US
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Unilever's pretax profit rises, but concern grows over sales. Unilever expects double-digit gain in net earnings
- Abstracts: Endesa's operating profit falls, while net rises on Edenor sale. Suez net profit increased 38% in first half
- Abstracts: Inditex's net profit increases by 31% to 91.7 million euros. Next posts healthy earnings in the first half of 2001
- Abstracts: A model to optimize project resource allocation by construction of a balanced histogram. Sensitivity analysis of scheduling algorithms
- Abstracts: Alcatel first-half profit fell 21% on increased research spending. Alcatel expects tough times to linger through next year